Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Louisville
This study will be a double-blind, prospective randomized pilot study. Subjects will be randomized on a 1:1 basis to receive routine asthma care with or without a magnesium drip.
Age
2–20
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 2 years 0 days up to 20 years 364 days
Clinical diagnosis of asthma including both of the following:
* Attending physician's primary working diagnosis is status asthmaticus
* Results of a modified International Study of Asthma and Allergies in Children (ISAAC) diagnostic questionnaire consistent with an asthma diagnosis
Planned PICU admission for moderate-to-severe asthma exacerbation persisting despite standard first-tier therapy (systemic corticosteroids and at least a one-hour treatment with nebulized albuterol/ipratroprium or equivalent) as evidenced by an asthma score of 7 or greater
IV access or equivalent
Ability to understand and give informed consent/assent in English
You may not be if
Prior enrollment in this study
Prior adverse reactions to magnesium
Use of systemic corticosteroids or magnesium in preceding 2 weeks, or administered at a transferring facility more than 3 hours prior to enrollment
Admission for inpatient asthma care in preceding 2 weeks
Hemodynamic instability, impending respiratory failure or intubation
Inability in children age 7 years or older to give assent due to a developmental delay or altered mental status
Significant renal or cardiac disease
Sickle cell anemia
Significant, active non-asthma pulmonary disease
Clareo Health | Pilot Study of Magnesium Infusions in Pediatric Asthma
